Cardium Therapeutics, Inc. (CXM) Addresses Significant International Market with Generx

Cardium Therapeutics’ Generx product candidate is a good example of the company’s strategy of acquiring and developing new and innovative bio-medical product opportunities addressing unmet medical needs on a worldwide basis.

Generx (alferminogene tadenovec, Ad5FGF-4) is a DNA-based angiogenic growth factor therapeutic for patients with advanced coronary artery disease. Basically, it stimulates the growth of supplemental collateral blood vessels in the heart, which enhances myocardial blood flow in heart patients. It involves a one-time intracoronary administration, using a standard cardiac infusion catheter, making it simple and cost effective to use. Unlike standard therapies for the heart, like nitrates and beta blockers that only provide transient relief of symptoms, Generx is a disease-modifying regenerative medicine that can result in structural and physiologic changes in the heart, specifically the growing of new blood vessels. It is being designed as a superior alternative for patients without access to or ability to pay for more costly and invasive surgical procedures to increase blood flow, a common problem in many countries with a less developed healthcare system. As such, Generx is currently being developed for international markets.

Generx has already been tested in clinical studies at more than one hundred medical centers in the U.S., Europe, and elsewhere, and is now part of a study in the Russia to evaluate its therapeutic effects on patients with myocardial ischemia due to coronary artery disease. The ASPIRE Phase 3 registration study is a controlled multi-center study conducted at up to eight leading cardiology centers in the Russian Federation, where the efficacy of Generx will be measured using rest and stress SPECT (Single-Photon Emission Computed Tomography) myocardial imaging to sensitively measure improvements in microvascular cardiac perfusion.

In addition to Generx and other products, the Cardium portfolio includes Excellagen, a new, FDA-cleared highly-refined fibrillar collagen-based topical gel (2.6%) designed to support favorable wound care management for use with diabetic and other ulcers, surgical and other wounds, as well as burns.

For additional information, visit www.CardiumTHX.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html